\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ follow\\-up\\ apparent\\.\\ hematuria\\ symptoms\\ resolved\\.\ \(0\)\
\-\ abnormal\\ study\\ with\\ development\\ of\\ thin\\ cortical\\ calcifications\\,\\ which\\ extend\\ into\\ the\\ medullary\\ spaces\\ along\\ the\\ columns\\ of\\ bertin\\,\\ as\\ well\\ as\\ heterogeneous\\ enhancement\\ of\\ the\\ kidneys\\ and\\ minimal\\ delayed\\ excretion\\.\ \(0\)\
\-\ the\\ overall\\ pattern\\ is\\ compatible\\ with\\ acute\\ cortical\\ necrosis\\.\ \(0\)\
\-\ cortical\\ nephrocalcinosis\\ due\\ to\\ acute\\ renal\\ cortical\\ necrosis\ \(0\)\
\-\ acute\\ renal\\ cortical\\ necrosis\ \(2\)\
\-\ primary\\/secondary\\ oxalosis\ \(0\)\
\-\ chronic\\ glomerulonephritis\ \(1\)\
\-\ alports\\ syndrome\\ \\(glomerulonephritis\\,\\ endstage\\ kidney\\ disease\\,\\ and\\ hearing\\ loss\\)\\ \ \(0\)\
\-\ intrarenal\\ infection\\ in\\ hiv\\+\ \(0\)\
\-\ amphotericin\\ b\ \(0\)\
\-\ acute\\/chronic\\ renal\\ allograft\\ rejection\ \(0\)\
\-\ autosomal\\ recessive\\ polycystic\\ disease\ \(0\)\
\-\ 50\\ yo\\ woman\\ with\\ history\\ of\\ retroperitoneal\\ paraganglioma\\,\\ s\\/p\\ resection\\.\\ patient\\ developed\\ gross\\ hematuria\\ one\\ week\\ post\\-op\\.\\ ct\\ for\\ hematuria\\ revealed\\ an\\ incidental\\ finding\\.\ \(0\)\
\-\ patient\\ had\\ episode\\ of\\ hypotension\\ during\\ paraganglioma\\ resection\\.\\ hypotension\\ hypothesized\\ to\\ have\\ induced\\ acute\\ renal\\ cortical\\ necrosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cortical\\:\\ 0\\.38363924926779086\ \(0\)\
\-\ necrosis\\:\\ 0\\.2723084624458641\ \(0\)\
\-\ acute\\:\\ 0\\.24089291072952684\ \(0\)\
\-\ hematuria\\:\\ 0\\.23629858231056214\ \(0\)\
\-\ glomerulonephritis\\:\\ 0\\.2264077044233322\ \(0\)\
\-\ renal\\:\\ 0\\.22184314153861995\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.19374675182934642\ \(0\)\
\-\ hypotension\\:\\ 0\\.1929140209127243\ \(0\)\
\-\ alports\\:\\ 0\\.1424278866542811\ \(0\)\
\-\ oxalosis\\:\\ 0\\.13609744937257762\ \(0\)\
\-\ endstage\\:\\ 0\\.12812204160388985\ \(0\)\
\-\ rejection\\:\\ 0\\.12527549536031327\ \(0\)\
\-\ hypothesized\\:\\ 0\\.12527549536031327\ \(0\)\
\-\ columns\\:\\ 0\\.1207839786297524\ \(0\)\
\-\ bertin\\:\\ 0\\.1207839786297524\ \(0\)\
\-\ allograft\\:\\ 0\\.1207839786297524\ \(0\)\
\-\ intrarenal\\:\\ 0\\.1144535413480489\ \(0\)\
\-\ resection\\:\\ 0\\.11417848629464473\ \(0\)\
\-\ amphotericin\\:\\ 0\\.1132038522116661\ \(0\)\
\-\ nephrocalcinosis\\:\\ 0\\.10812310406634539\ \(0\)\
\-\ chronic\\:\\ 0\\.10572809788124925\ \(0\)\
\-\ recessive\\:\\ 0\\.10363158733578454\ \(0\)\
\-\ excretion\\:\\ 0\\.10122486677940538\ \(0\)\
\-\ polycystic\\:\\ 0\\.09416812275655069\ \(0\)\
\-\ autosomal\\:\\ 0\\.09186311447772703\ \(0\)\
\-\ compatible\\:\\ 0\\.08906767394062078\ \(0\)\
\-\ induced\\:\\ 0\\.08831811659295934\ \(0\)\
\-\ of\\:\\ 0\\.08714419241159638\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.08584185124726636\ \(0\)\
\-\ extend\\:\\ 0\\.08215116540597088\ \(0\)\
\-\ overall\\:\\ 0\\.08182588740344345\ \(0\)\
\-\ episode\\:\\ 0\\.08150724819314367\ \(0\)\
\-\ spaces\\:\\ 0\\.08104116046546268\ \(0\)\
\-\ hearing\\:\\ 0\\.08088883945838732\ \(0\)\
\-\ resolved\\:\\ 0\\.08000486115728109\ \(0\)\
\-\ gross\\:\\ 0\\.07903308572029194\ \(0\)\
\-\ medullary\\:\\ 0\\.07876619410352072\ \(0\)\
\-\ kidneys\\:\\ 0\\.07666486772198626\ \(0\)\
\-\ disease\\:\\ 0\\.07476926625319169\ \(0\)\
\-\ apparent\\:\\ 0\\.07450795696515335\ \(0\)\
\-\ development\\:\\ 0\\.07362675122972515\ \(0\)\
\-\ as\\:\\ 0\\.07155790842744171\ \(0\)\
\-\ the\\:\\ 0\\.07108356593010727\ \(0\)\
\-\ delayed\\:\\ 0\\.06969246032222469\ \(0\)\
\-\ thin\\:\\ 0\\.06932680474784882\ \(0\)\
\-\ minimal\\:\\ 0\\.06794424009125635\ \(0\)\
\-\ pattern\\:\\ 0\\.06649231005206183\ \(0\)\
\-\ developed\\:\\ 0\\.06607594459375077\ \(0\)\
\-\ incidental\\:\\ 0\\.06601735998697639\ \(0\)\
\-\ calcifications\\:\\ 0\\.06499877411200303\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.06446034905312945\ \(0\)\
\-\ kidney\\:\\ 0\\.06256859332673749\ \(0\)\
\-\ 50\\:\\ 0\\.062197946142342884\ \(0\)\
\-\ week\\:\\ 0\\.059902816243719854\ \(0\)\
\-\ along\\:\\ 0\\.05966744325248244\ \(0\)\
\-\ study\\:\\ 0\\.05939725244093397\ \(0\)\
\-\ finding\\:\\ 0\\.058541033322777915\ \(0\)\
\-\ revealed\\:\\ 0\\.058396803388197166\ \(0\)\
\-\ patient\\:\\ 0\\.05793412800342584\ \(0\)\
\-\ during\\:\\ 0\\.056411022001482784\ \(0\)\
\-\ yo\\:\\ 0\\.055640244594810526\ \(0\)\
\-\ loss\\:\\ 0\\.05425920962806264\ \(0\)\
\-\ infection\\:\\ 0\\.05379798190956836\ \(0\)\
\-\ syndrome\\:\\ 0\\.05369140962282615\ \(0\)\
\-\ abnormal\\:\\ 0\\.0535066408464279\ \(0\)\
\-\ with\\:\\ 0\\.052317756627478194\ \(0\)\
\-\ enhancement\\:\\ 0\\.051261946485023954\ \(0\)\
\-\ due\\:\\ 0\\.051193916837580046\ \(0\)\
\-\ one\\:\\ 0\\.05099158857124247\ \(0\)\
\-\ symptoms\\:\\ 0\\.04872912015948201\ \(0\)\
\-\ into\\:\\ 0\\.04734328080451435\ \(0\)\
\-\ woman\\:\\ 0\\.04638324665026804\ \(0\)\
\-\ to\\:\\ 0\\.04453013730184168\ \(0\)\
\-\ have\\:\\ 0\\.04449084183416985\ \(0\)\
\-\ had\\:\\ 0\\.044373451962447664\ \(0\)\
\-\ well\\:\\ 0\\.043123762826064865\ \(0\)\
\-\ which\\:\\ 0\\.040496911162800936\ \(0\)\
\-\ and\\:\\ 0\\.036806719969668694\ \(0\)\
\-\ an\\:\\ 0\\.03405661764665902\ \(0\)\
\-\ history\\:\\ 0\\.034026448015268766\ \(0\)\
\-\ ct\\:\\ 0\\.033906349120091855\ \(0\)\
\-\ no\\:\\ 0\\.028961615465839714\ \(0\)\
\-\ for\\:\\ 0\\.02699369781823095\ \(0\)\
\-\ is\\:\\ 0\\.024389952913154767\ \(0\)\
\-\ in\\:\\ 0\\.022155480029133548\ \(0\)\
